Novartis

Name of the program: 
Novartis Foundation for Sustainable Development
Sector in which the organization works: 
Pharmaceutical
Short description of the organization and its work to control and eliminate NTDs: 

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

The Novartis Foundation for Sustainable Development is a nonprofit organization whose activities form part of the Corporate Responsibility portfolio of Novartis AG. For over 30 years, the Novartis Foundation has served as a competence center for corporate responsibility and international health, focused on underserved communities. The Novartis Foundation aims to improve access to healthcare, strengthen human resources in health and empower vulnerable groups. The foundation also fosters dialogue and networking, acting as a bridge between the private sector, international organizations, governments and NGOs.

Novartis and the Novartis Foundation have a long-term commitment to leprosy treatment and control, having provided over USD 110 million for patients worldwide to date. Since 2000, through the World Health Organization (WHO), Novartis has donated multidrug therapy (MDT) valued at over USD 80 million, helping to treat over 5 million patients. In 2012, Novartis continued its work with the WHO by extending its drug donation program through the year 2020. The Novartis Foundation has been active in the fight against leprosy for more than 25 years, providing more than CHF 30 million to help reduce the stigma attached to leprosy, prevent disabilities and help patients reintegrate in society. To help go the last mile in leprosy elimination, the Novartis Foundation launched a new strategy focusing on interrupting leprosy transmission through:

  • Early diagnosis and prompt treatment.
  • Tracing and prophylactic treatment of contacts of newly diagnosed patients.
  • Diagnostic tools and strict surveillance and response.

For more information, please visit: www.novartisfoundation.org and www.youtube.com/novartisfoundation

Novartis is one of the 20 original endorsers of the London Declaration